CD274 and non-small cell lung carcinoma: The incorporation of threshold inclusion criteria based on the expression level of PD-L1 protein was approved in 2015, for the treatment of patients with PD-L1-positive NSCLC as determined by an FDA-approved test along with the approval of the PD-L1 IHC 22C3 pharmDx (Dako).